5def19a5-a8b7-456d-99e3-99ff81d19571_Atomera-Premium-Analysis-v.2.pdf
Atomera: Premium Analysis
Atomera
Please note that small cap stocks can be extremely volatile and high risk. Atomera has a market cap of $160 million with a current price-to-sales of 254. The forward price-to-sales is 29. This illustrates that a small cap needs very little revenue growth to move from an outsized valuation to one that is more aligned with the market. This also represents a fair amount of speculation as the forward price-to-sales is determined from a consensus of two analysts who are counting on deals moving through the pipeline. There is no guarantee this will happen.
Atomera’s extreme volatility was on display last week. The stock climbed 24% before erasing those gains by market close. Last month, Atomera offered 1.76 million shares for $5.00 per share to raise $8.8 million. This led to a 13% drop. Additionally, Atomera is expecting no revenue in Q2 due to the effects of the coronavirus. This could add to volatility.
I am covering Atomera because I feel like there are some gains to be had in the breakup between Huawei and Western countries. There is a major restructuring going on. I also like how the market is attempting to price this company right now. We may wait until after the first Phase 4 deal (see below), as there will be plenty of runway left.
Technical analysis can often be less important when a trend is in play and the story is well known. However, for stocks like Atomera, technical analysis is crucial. Knox will be updating our readers this weekend and as we go along on this company.
Please note, as one reader pointed out on the forum, there are bearish comments online about design challenges around MST. These comments are likely correct to some extent and the question is if the company can overcome them. I’ve included more information under the subheading “Design Challenges” below.
I am still initiating coverage and asking Knox to track this stock for an entry because I am comfortable with the iteration process for technologies that solve big problems. The semiconductor market is old fashioned and moves very slowly at times around new processes. However, I am especially keen to find worthy stocks that help strengthen the domestic semiconductor market as China tensions heat up.
Financials
Atomera’s revenue in Q1 2020 was $62,000 compared to $71,000 in the year-ago quarter. For Q4, the revenue was $138,000 compared to $150,000 in the year-ago quarter.
The company’s net loss is $3.6 million per share, or negative ($0.22) EPS. Adjusted EBITDA was a loss of $2.9 million.
The company has cash and cash equivalents of $11.4 million as of March 31, 2020. As mentioned, ATOM recently issued shares at $5.00, for gross proceeds of $8.8 million.
For the full year 2019, revenue was $533,000 compared to $246,000 in fiscal 2018. Net loss was ($0.84) EPS in FY 2019 compared to ($1.02) EPS in FY 2018. TTM revenue is slightly down from FY 2019 at $520,000 and ($0.83) EPS.
The median forward revenue estimate from two analysts is $786,000 for 2020 with one analyst projecting $5.45 million in 2021. It’s the second estimate that makes Atomera exciting although the road may be bumpy between now and 2021.
Roth Capital is the bullish analyst: “We regard ATOM as a highly differentiated silicon enhancement IP vendor that is gaining traction with large semiconductor supply chain companies. We believe the company continues to make solid progress across its significant base of engagements. We expect ATOM to continue to convert additional engagements to licensing revenue over the next few quarters. We maintain our Buy rating.”
Forward EPS estimates for 2020 is ($0.71) and ($0.61).
Integrated License Agreements
Revenue is generated from integrated license agreements. Customers pay a licensing fee to use MST technology in the manufacturing of silicon wafers. Royalties are paid for each silicon wafer or device that incorporates the MST technology (see below for more on MST). The company also generates revenue through engineering services revenue.
According to the 2019 Investors Presentation, the company has an addressable market of $6-$7 billion in royalty fees primarily driven by FinFET and Advanced Nodes ($6 billion), RF SOI ($50 million) and 5V Analog ($660 million).
Please note: I’ve reached out to Investor Relations to confirm these numbers have not changed from any design challenges and will update as we go along.
Total addressable market as of 2018 was $7 billion at 2-3% licensing fees, or $140 million. The 5V analog market adds another $660 million to the addressable market figured on a market size of $33 billion.
Valuation
The gamble that Phase 4 deals will go through is best understood when looking at the spread between forward PS ratio of 200 with the PS ratio in 2021 at 29. Due to Atomera’s tiny revenue of roughly $520,000-$530,000 per year, Phase 4 deals are imperative to reach the 1-year forward price-to-sales (i.e. this is an all or nothing stock).

Customer Pipeline
As of now, there are 19 customers with 26 engagements with 16 in Phase 3 (integration). The more bullish moves around this stock are due to the Phase 3 deals the company has in the pipeline. It would be easy to presume the Phase 3 deals are with larger semiconductor companies as Atomera has a very specific use for its product. TMSC is used often as an example in their Investor Presentations.
According to the March 2020 Investors Presentation, the company is engaged with 50% of the world’s top semiconductor markets. The company states Asahi Kasei Microdevices and STMicroelectronics have licensed the technology plus “a large fabless semiconductor company” for mobile 5G markets.

The coronavirus is a challenge for Atomera as the customers in Phase 3 are cautious with budgest. There is also a slight delay in R&D engineering for new programs. As the company explained on the earnings call, the production personnel are in the fab, but development engineers continue to work from home, which can limit the ability to start new R&D lots.
Per the management, “where some customers would normally be starting wafers, they may be holding back until their engineers get back into the office to start pulling the levers on new lots.”
Here is what the company said about the coronavirus: “Due to the delays created by the coronavirus travel restrictions and the impact on our customer’s business, we are now expecting to have no revenue in Q2 2020. But as Scott indicated in his remarks, none of our customers have ceased work on MST and progress on the JDA contracts has been delayed but not canceled.”
Therefore, any investment in Atomera is a gamble on the company moving one or more customers to Phase 4 (installation). If/when the company moves to Phase 4 through Phase 6 (production), revenue levels become much more attractive.
Notably, it can be viewed as concerning that the company held a secondary offering at $5.00 a share before securing a Phase 4 deal. On the other hand, this may be to buy time and create a necessary financial cushion as covid-19 delays budgets and capex/R&D spending.
Product
Mears Silicon Technology (MST) is a performance enhancing technology that the company believes helps integrated circuits overcome a number of key engineering challenges.
Primarily, MST enhances transistor capabilities and reduces chip size. According to Atomera and a third-party study by PMIC published on their website, MST can result in a 16-21% reduced chip size.
MST allows DRAM designers to reduce chip size without moving to a new technology node. According to Atomera, the IDM process/development is $10 million and the foundry equipment upgrade is $30 to $50 million. Meanwhile, a foundry for a new node can cost billions.

MST is also beneficial in stopping dopant diffusion in high temperature manufacturing, which makes it helpful in chip designs. According to Tailwinds research, MST could become an essential element in FinFET production processes, as dopant diffusion is a major issue. The three major companies who have explored FinFET are Intel, Samsung and TSMC.
According to Atomera, Mixed-Signal/RF devices can also achieve a 10-11% die size reduction. This is achieved with a lattice design that increases horizontal current flow and reduces vertical leakage.
The CEO grew a $1 billion-plus division at Broadcom and also worked as an SVP and GM at Altera. The CTO has been inventing and working on patents for broadband networks for 30 years. I don’t see any flags with the management (a common issue with small caps).
Design Challenges
Atomera is as high-tech as a company and concept can be. Obviously, there are design challenges to overcome or the company would be generating more sales and would no longer be a tiny cap company. What I look for here is whether there will be enough demand to overcome the design challenges and to support the iteration process. I believe there is with the recent pressure on more domestic semiconductor manufacturing.
There is an ongoing debate sparked on a thread by an anonymous commenter on Seeking Alpha. The comment asserts: “High temperatures of older nodes won’t let their concept survive. Finer nodes with finfets/nanowires don't need it.” The comments state that Atomera’s advantage lies in “surface inversion devices whereas finfet/nanowires are volume inverted.”
I try to stay as neutral as possible and weigh both sides of a debate like this. The truth is this company could go either way – boom or bust — but probably not much in-between.
One thing I like about passionate bulls/investors and passionate bears/short sellers is they always bring to the surface the major catalysts or risks.
Here is what Atomera’s Investor Relations team said when I inquired about these issues: “MST1 and MST2 have different properties for handling thermal budgets, depending on the application. There is a lot of variability in customer processes and thermal budgets, and Atomera has worked with enough to have a good sense of how to navigate these types of engineering challenges.”
Below is what one of Atomera’s investors said (who also writes analysis). I’m pasting sections from his blog on the topic below. You can read the full blog here: “Are All the Atoms Aligned for Atomera?”
“The first potential issue to be addressed relates to diffusion of oxygen in high-temperature processes. Which translates roughly into the question of can MST be applied to chips that have high heat during manufacturing? The concern here is that many production lines have stages in which chips are subject to annealing at very high temperatures. If the thin layer of oxygen that Atomera applies were to be diffused in these processes, this would greatly diminish if not alleviate all the benefits of MST. Taking it one step further, if MST is not going to be used in high-heat process manufacturing, the applicable market for MST would be greatly diminished making this truly only a niche product.
From my digging, it appears that this concern is very overblown but not completely without merit.
Atomera has developed a work-around solution whereby they can apply MST at later stages in the process, thereby missing out on the high temperature steps that could diffuse the oxygen. This actually was discussed on ATOM’s Q2 2018 earnings call. Here’s what they said about this issue…
“I’m very pleased to tell you that during the last quarter, Atomera has started testing an optimized version of our film that shows remarkable potential by attacking the problem in a new way. Our approach has been to find a new material construction method that’s better at oxygen retention so it’s able to withstand a wider spectrum of processes surrounding MST…This should make it easier for customers to see better results earlier in their integration process and gain higher confidence in MST’s ability to withstand manufacturing variances during mass production which is a critical factor in their decision of whether to adopt our technology.”“I’m very pleased to tell you that during the last quarter, Atomera has started testing an optimized version of our film that shows remarkable potential by attacking the problem in a new way. Our approach has been to find a new material construction method that’s better at oxygen retention so it’s able to withstand a wider spectrum of processes surrounding MST…This should make it easier for customers to see better results earlier in their integration process and gain higher confidence in MST’s ability to withstand manufacturing variances during mass production which is a critical factor in their decision of whether to adopt our technology.”
I can also confirm that during conversations with management, they have specifically noted that oxygen diffusion is a potential issue, but they are very confident in their ability to deal with this. However, applying MST after annealing will certainly place constraints on the process. Some potential customers will need annealing too late, in the process, for MST to help them. Dopant implantation messes with the crystals, annealing heals them. Is it possible for doping to be accomplished without high energy, destructive implants? Maybe. But if not, how many customers are impacted by this?
At this time, I’m sure Atomera knows how big this potential issue is through their customer interactions, but it’s impossible for outsiders to have this knowledge. Having listened to the Company and learned what I can about semiconductor manufacturing processes, it seems likely that the truth lies somewhere between MST being a niche product and it working on any and all processes. I lean in favor of the market being much larger than some concerns have expressed.
Another issue mentioned by investors related to the stage of the product. Namely, all the white papers reporting the great gains of MST were based on simulations. Which implies that the process has yet to be replicated in the real world. Once again, here’s CEO Scott Bibaud, this time on last quarter’s conference call…
“These papers are based on simulation models and only limited experimental results since the advanced process nodes are not widely accessible and are extremely expensive, but they all show impressive performance improvements with MST. Over the last few months, we’ve had multiple test results from actual silicon runs, which have validated those fundamental mechanisms.”“These papers are based on simulation models and only limited experimental results since the advanced process nodes are not widely accessible and are extremely expensive, but they all show impressive performance improvements with MST. Over the last few months, we’ve had multiple test results from actual silicon runs, which have validated those fundamental mechanisms.”
So, yeah, it’s true that the papers were based on simulations, but Atomera has run their process on customer silicon many times. The theoretical gains were seen in these runs. However, “customer silicon” is, by definition, not Atomera’s. The data obtained from these trials is not Atomera’s to share with the world, and I don’t think a semiconductor company would be sharing their test results
from a new process with their competitors. So, we’ve not seen the actual numbers from silicon runs and will need to base confidence here on management’s statements that those numbers are consistent with simulations.”
Conclusion:
This is a true Hail Mary small cap idea. The stock’s potential hinges on Phase 4 deals coming through (already a gamble) meanwhile the coronavirus may have delayed orders.
However, one or two Phase 4 deals can really move the stock price for this company. The June 2019 investors report provided two scenarios showing $6.7 million in revenue up to $29 million in revenue as a result of signing one large customer.
From a high-level overview, I like this company right now (given the ample risks) because I am keen to invest in the increasing pressure on semiconductor companies to reduce dependency on China and to make up for Huawei’s dominance. As one Seeking Alpha comment had also pointed out, the semiconductor industry can be slow to adopt new technologies. This is very true, however, the geopolitical tensions will put pressure on the manufacturing process.
It’s important to emphasize that if Atomera signs a Phase 4 deal, there will still be time to invest. To reduce risk, we may explore waiting until the first Phase 4 deal is signed OR we will wait for a very clear technical breakout. We are not front-running this stock based on fundamentals.
Knox is essential to navigate this and he will write a blog update on the technicals (and what he’s looking for) this weekend.








